



The HMA Working Group on Product Testing has been working since the adoption of its mandate by HMA in November 2008 on principles for the improvement of the quality control of medicines through the sharing of information and work among EEA regulatory authorities and through the strengthening of cooperation between inspection, assessment and OMCLs within the European Medicines Regulatory Network.

One of its goals has been to explore the possibility for future evolution of the programs of product testing of MRP/DCP authorised products already in place making concrete proposals for further improvements with the aim to increase the number of Member States that benefit from the program in terms of resource savings and of use of more comprehensive information for better risk-based inspection and assessment.

The working group believes that mutual recognition of control results between Competent Authorities is one of the key components of a collaborative approach to the sampling and testing of medicinal products between EEA regulatory authorities.

At its October 2009 meeting in Uppsala HMA supported the risk-based approach for selection of MRP/DCP products for testing and endorsed the document on Mutual Recognition of Control Results.

The document is now presented to the OMCL's representatives for implementation of its principles.

Jean Marimbert
Chair of the HMA WGPT

Susanne Keitel
Director of EDQM